Daniel Morgenstern, Associate Professor at University of Toronto, shared a post on LinkedIn:
“Very sad that due to changes in funding rules, Canadian (and Australian) participation in the Children’s Oncology Group early phase trials portfolio has been suspended. Fingers crossed that we can find a way to work through this and again participate so that we can continue to maximise availability of novel therapies for Canadian children and contribute to scientific advances.”
More posts featuring Clinical Trials on OncoDaily.